Abstract
The OPG/RANK/RANKL axis is now recognized as a master regulator of bone remodeling, controlling osteoclast's maturation and extracellular matrix calcification. Nevertheless, a number of clinical and basic science studies conducted in the last few years demonstrated that the triad could be also involved in several physiological and pathological processes outside the bone tissue. In particular, evidences have been collected showing an active participation of OPG and RANKL in vascular pathology, including atherogenesis and arterial calcification. A series of epidemiological studies also showed that increased circulating levels of OPG are associated with significant, independent predictive value for future cardiovascular mortality/morbidity. However, the human studies did not unravel whether OPG should be considered as a promoter, a protective mechanism or is instead neutral with regard of vascular disease progression. Main objective of the present review is to summarize findings from both in vivo and in vitro investigations on the role played by OPG in vascular disease progression and to delineate a plausible scenario on the actual involvement of the OPG/RANK/RANKL triad and TRAIL in cardiovascular pathology.
Keywords: OPG, atherogenesis, vascular calcification.
Current Pharmaceutical Design
Title:Osteoprotegerin in Cardiovascular Disease: Ally or Enemy?
Volume: 20 Issue: 37
Author(s): Giacomo Buso, Elisabetta Faggin, Paolo Pauletto and Marcello Rattazzi
Affiliation:
Keywords: OPG, atherogenesis, vascular calcification.
Abstract: The OPG/RANK/RANKL axis is now recognized as a master regulator of bone remodeling, controlling osteoclast's maturation and extracellular matrix calcification. Nevertheless, a number of clinical and basic science studies conducted in the last few years demonstrated that the triad could be also involved in several physiological and pathological processes outside the bone tissue. In particular, evidences have been collected showing an active participation of OPG and RANKL in vascular pathology, including atherogenesis and arterial calcification. A series of epidemiological studies also showed that increased circulating levels of OPG are associated with significant, independent predictive value for future cardiovascular mortality/morbidity. However, the human studies did not unravel whether OPG should be considered as a promoter, a protective mechanism or is instead neutral with regard of vascular disease progression. Main objective of the present review is to summarize findings from both in vivo and in vitro investigations on the role played by OPG in vascular disease progression and to delineate a plausible scenario on the actual involvement of the OPG/RANK/RANKL triad and TRAIL in cardiovascular pathology.
Export Options
About this article
Cite this article as:
Buso Giacomo, Faggin Elisabetta, Pauletto Paolo and Rattazzi Marcello, Osteoprotegerin in Cardiovascular Disease: Ally or Enemy?, Current Pharmaceutical Design 2014; 20 (37) . https://dx.doi.org/10.2174/1381612820666140212195711
DOI https://dx.doi.org/10.2174/1381612820666140212195711 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process
Current Topics in Medicinal Chemistry Endothelin-Converting Enzyme Inhibitors
Current Enzyme Inhibition Nitric Oxide: News from Stem Cells to Platelets
Current Medicinal Chemistry The Effect of Statin Therapy on Arterial Stiffness by Measuring Pulse Wave Velocity: A Systematic Review
Current Vascular Pharmacology Arecoline Increases the Production of Nitric Oxide and Post-Translational S-Nitrosoproteome in Endothelial Cells
Current Proteomics Natriuretic Peptides in Coronary Disease With Non-ST Elevation: New Tools Ready for Clinical Application?
Recent Patents on Cardiovascular Drug Discovery Important Hints in Behavioural Teratology of Rodents
Current Pharmaceutical Design Preparation and in vitro Evaluation of α and β -Amyrins Loaded Nanoemulsions
Current Pharmaceutical Biotechnology Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System
Current Psychiatry Reviews Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome
Current Pharmaceutical Design Can Imaging Techniques Identify Smoking-Related Cardiovascular Disease?
Current Pharmaceutical Design Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design Targeting Redox Signaling in the Vascular Wall: From Basic Science to Clinical Practice
Current Pharmaceutical Design FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Cardiac-Specific Expression of the Hepatocyte Growth Factor (HGF) Under the Control of a TnIc Promoter Confers a Heart Protective Effect After Myocardial Infarction (MI)
Current Gene Therapy Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research The Nitric Oxide Signaling Pathway in the Penis
Current Pharmaceutical Design An Introduction to Obesity and Dementia
Current Alzheimer Research Pharmacoproteomics in Cardiac Hypertrophy and Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia
Current Vascular Pharmacology